Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition

Key Takeaways TMO faces margin pressure from weak macro trends, supply disruptions and rising operating expenses. Foreign exchange volatility and global expansion heighten risk to Thermo Fisher's international revenues. TMO's $4.1B Solventum deal aims to boost biologics growth and deliver $125M in synergy over five years.Thermo Fisher (TMO) suffers from macroeconomic issues. Also, competitive headwinds and currency fluctuations continue to dampen top-line growth. The stock carries a Zacks Rank #4 (Sell) c ...